Kent Blakely, MD

CONDITIONS

• Psoriatic arthritis
• Inflammatory arthritis
• Autoimmune rheumatic diseases
• Persistent joint inflammation, swelling, and stiffness suggestive of inflammatory pathology
• Osteoporosis
• Patients at elevated risk for fragility fractures

TREATMENTS

• Biologic therapy initiation and management
• Disease-Modifying Antirheumatic Drug (DMARD) therapy
• Treatment monitoring and medication optimization
• Evidence-based osteoporosis pharmacotherapy
• Collaborative management with primary care and specialty providers

AREAS OF FOCUS

• Early diagnosis and management of inflammatory arthritides
• Longitudinal management of autoimmune rheumatic disease
• Disease activity assessment and treatment optimization
• Osteoporosis evaluation and fracture risk stratification
• Prevention of osteoporotic and fragility fractures
• Bone health preservation and monitoring

PRACTICE SCOPE

• Focused on inflammatory rheumatic diseases and osteoporosis management, not a chronic pain management or chronic fatigue referral service

REFERRAL CONSIDERATIONS

• Suspected inflammatory arthritis
• Rheumatoid arthritis requiringspe cialty management therapy
• Psoriatic arthritis evaluation or treatment optimization
• Autoimmune rheumatic disease assessment
• Osteoporosis with elevated fracture risk
• History of fragility fracture or concern for future fracture risk

Good Shepherd Rheumatology
Good Shepherd Medical Plaza
620 NW 11th St., Suite M-013
Hermiston, OR 97838

Phone: 541.667.3887
Fax: 458.219.3129